Cargando…
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of anticancer agent that have demonstrated activity in hematological malignancies. Here, we investigated the efficacy and safety of HDACi (vori...
Autores principales: | Matthews, G M, Lefebure, M, Doyle, M A, Shortt, J, Ellul, J, Chesi, M, Banks, K-M, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, P L, Johnstone, R W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789166/ https://www.ncbi.nlm.nih.gov/pubmed/24030150 http://dx.doi.org/10.1038/cddis.2013.306 |
Ejemplares similares
-
ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011) -
Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016) -
Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014) -
Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022) -
Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin
por: Li, Geqiang, et al.
Publicado: (2010)